Copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2000
In their recent article, Miller et al1 highlight the relatively low and unchanged use of lipid-lowering agents among patients with coronary artery disease (CAD) at academic medical centers between 1994 and 1997. The picture appears disappointing overall and for women in particular. However, the use of lipid-lowering therapy (LLT) in the real world might be even less frequent. In fact, it is our opinion that the treatment figures obtained might be overestimations. First, patients participating in controlled clinical trials are usually highly motivated and more compliant with treatment than the general population. Second, the study involved medical centers of excellence in the United States and Canada. Third, when the results of the Scandinavian Simvastatin Survival Study were published in November 1994, a letter was distributed to all Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) investigators, thereby increasing the likelihood of physicians putting those recommendations into practice.
Sgadari A, Incalzi RA, Onder G, Pedone C, Gambassi G. Lipid-Lowering Therapy in Patients With Coronary Artery Disease: Sex or Age Bias? Arch Intern Med. 2000;160(17):2684–2685. doi:
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: